{
  "id": "56bb68a5ac7ad1001900000a",
  "type": "yesno",
  "question": "Is nivolumab used for treatment of Non\u2013Small-Cell Lung Cancer?",
  "ideal_answer": "Yes, nivolumab used for treatment of Non\u2013Small-Cell Lung Cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26028407",
    "http://www.ncbi.nlm.nih.gov/pubmed/25897158",
    "http://www.ncbi.nlm.nih.gov/pubmed/24685885",
    "http://www.ncbi.nlm.nih.gov/pubmed/25704439",
    "http://www.ncbi.nlm.nih.gov/pubmed/25965365",
    "http://www.ncbi.nlm.nih.gov/pubmed/24402925",
    "http://www.ncbi.nlm.nih.gov/pubmed/25496336"
  ],
  "snippets": [
    {
      "text": "BACKGROUND: Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, as compared with docetaxel in this patient population.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26028407",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26028407",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Agents currently in active clinical development for lung cancer include ipilimumab, which modulates the cytotoxic T-lymphocyte-associated antigen 4 pathway, and multiple agents targeting the programmed death protein 1 (PD-1) pathway, both anti-PD-1 compounds (nivolumab, pembrolizumab [MK-3475]) and those that target programmed death ligand 1 (PD-L1), a key ligand for PD-1 (BMS-936559, MPDL3280A).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24685885",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25897158",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We report overall survival (OS), response durability, and long-term safety in patients with non-small-cell lung cancer (NSCLC) receiving nivolumab in this trial.PATIENTS AND METHODS: Patients (N = 129) with heavily pretreated advanced NSCLC received nivolumab 1, 3, or 10 mg/kg intravenously once every 2 weeks in 8-week cycles for up to 96 weeks. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25897158",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: Nivolumab monotherapy produced durable responses and encouraging survival rates in patients with heavily pretreated NSCLC. Randomized clinical trials with nivolumab in advanced NSCLC are ongoing.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25897158",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two PD-1 inhibitors, Bristol-Myers Squibb's nivolumab and Merck's MK-3475, both demonstrated positive results in phase I trials of previously treated patients with non-small cell lung cancer, reported at the World Conference on Lung Cancer in Sydney, Australia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24402925",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, many trials addressed the role of such therapies for metastatic NSCLC treatment: ipilimumab, tremelimumab, nivolumab and lambrolizumab are immunotherapeutic agents of main interest in this field.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496336",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two PD-1 inhibitors, Bristol-Myers Squibb&apos;s nivolumab and Merck&apos;s MK-3475, both demonstrated positive results in phase I trials of previously treated patients with non-small cell lung cancer, reported at the World Conference on Lung Cancer in Sydney, Australia",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24402925",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nivolumab, pembrolizumab (formerly known as MK-3475 and lambrolizumab), and pidilizumab are anti-PD-1 antibodies in clinical development for melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck cancers, lymphoma, and several other cancers",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25965365",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26028407",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25704439",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced, refractory, squamous non-small-cell lung cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25704439",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced, refractory, squamous non-small cell lung cancer. These data support the assessment of nivolumab in randomised, controlled, phase 3 studies of first-line and second-line treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25704439",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002289",
    "http://www.disease-ontology.org/api/metadata/DOID:3908"
  ],
  "exact_answer": "Yes"
}